Prevention of thrombosis in ambulatory patients with cancer.
Cancer patients with solid tumors or hematologic malignancies receive most of their cancer treatment as outpatients. Thromboembolism, when it occurs, complicates the clinical care of these patients because of the associated morbidity and the need for anticoagulant treatment. It would seem that prevention of venous thromboembolism in these patients would be worthwhile. However, to date there are relatively few trials of anticoagulant prophylaxis in ambulatory patients with cancer and it is not possible to recommend prophylaxis for most patients. Research is needed to better define a population at high enough risk to warrant pharmacologic prophylaxis and to develop new antithrombotic agents for this indication.
Rana
Punam
P
Department of Oncology, McMaster University and Juravinski Cancer Centre, Hamilton, Ontario, Canada.
Levine
Mark N
MN
D000328:Adult; D000367:Age Factors; D000368:Aged; D000553:Ambulatory Care / Q000379:methods*; D000925:Anticoagulants / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D019337:Hematologic Neoplasms / Q000150:complications / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D011322:Primary Prevention / Q000379:methods*; D018570:Risk Assessment; D016019:Survival Analysis; D020246:Venous Thrombosis / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*
D000925:Anticoagulants; D000970:Antineoplastic Agents